Chembio Diagnostics Reports First Quarter 2015 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Chembio Diagnostics Reports First Quarter 2015 Financial Results

MEDFORD, N.Y., May 7, 2015 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI ), a leader in point-of-care diagnostic tests for infectious diseases, today reported financial results for the three months ended March 31, 2015.

John J. Sperzel III, Chembio's Chief Executive Officer, stated, "In the first quarter, we achieved multiple important growth metrics. During the period our total revenue was $6.23 million, an increase of 7.2% as compared to Q1 2014. Product revenue for Q1 2015 was $5.61 million, an increase of 14.5% as compared to Q1 2014. One of the most important measures for the Company is DPP ® revenue which was $2.46 million during Q1 2015, an increase of 110.7% compared to Q1 2014. We are also pleased to report an increase in product gross margin from 27.8% in the first quarter of 2014 to 36.9% for the first quarter of 2015."

Mr. Sperzel continued, "Contributing to our sales growth is the fact that Chembio's product portfolio is the strongest it's ever been. Today, we have 100% control of our DPP ® products and STAT-PAK ® products on a worldwide basis. Also, as announced in January 2015, we finalized an agreement to regain full rights related to the SURE CHECK ® HIV 1/2 Assay, including sales, marketing, distribution, manufacturing and trademark rights, which will become effective June 1, 2016. The DPP ® , STAT-PAK ® and SURE CHECK ® HIV Assays are all approved by the U.S. Food and Drug Administration (FDA) and CLIA-waived for the detection of antibodies to HIV 1 and HIV 2. Most important, our assays are recognized as high quality products and some of the most important tools in the fight against HIV and other infectious diseases. Just recently, the AIDS Institute / New York State Department of Health added DPP ® HIV 1/2 Assay to the list of CLIA-waived HIV rapid tests that are approved for funding, making it the only oral fluid HIV rapid test on the list. We are proud to have the respect of the healthcare community and it is our goal to preserve and strengthen this reputation in the U.S. and around the world.

"Although, as discussed below, our net loss of $647,000 represents an increase in net loss of $422,000 in Q1 2015 over Q1 2014, a large portion of this increase is attributable to increased R&D, and sales and marketing, expenses that we believe will inure to Chembio's benefit in the future.

"Our decisions and execution in 2014 paved the way to new partners, new products and new markets. During the first quarter of 2015 we observed significant, and in some cases, tremendous growth in total revenue, product revenue, DPP ® revenue and product gross margins. Our collaboration programs, as well as our internal development programs are advancing – each moving a step closer to adding value to the Chembio pipeline. The first quarter of 2015 provided a strong signal validating our strategy, commercialization organization, products, team and, most importantly, our capabilities. More so than ever, we believe we are on the path to brand expansion and global growth."

Financial information comparing the 2015 first quarter to the 2014 first quarter:

  • Total revenues of $6.23 million, compared with $5.81 million (an increase of 7.2%).
  • Product sales of $5.61 million, compared with $4.90 million (an increase of 14.5%).
  • Operating loss of $875,000, compared with operating loss of $383,000
  • Net loss of $647,000, or $0.07 per diluted share, compared with net loss of $225,000, or $0.02 per diluted share

Additional First Quarter 2015 Information

Total revenues for the first quarter of 2015 of $6.23 million were up 7.2% compared with total revenues of $5.81 million in the prior-year period. Product sales in the 2015 first quarter of $5.61 million were up 14.5% compared with product sales of $4.90 million in the prior-year period. R&D milestone, and grant and royalty revenues for the three months ended March 31, 2015 decreased to $616,000 from $909,000 in the prior-year period.

Gross margin dollars for the 2015 first quarter increased 18% to $2.69 million compared with $2.27 million for the prior-year period, due primarily to the increase in product sales. The amount of product gross margin for the first quarter of 2015 increased 51.8% to $2.07 million, from $1.36 million in the prior-year period.

R&D expenses in the first quarter of 2015 were $1.58 million, compared with $1.20 million in the prior-year period. This increase is due primarily to increased R&D activities for projects and grants.

Selling, general and administrative expenses in the first quarter of 2015 increased to $1.98 million from $1.48 million in the prior-year period, largely due to increased commissions on DPP® sales, wages and related costs and increased travel expenses.

Operating loss for the first quarter of 2015 was $875,000, compared with an operating loss of $383,000 for the prior-year period.

Net loss for the first quarter of 2015 was $647,000, or $0.07 per diluted share, compared with net loss of $225,000, or $0.02 per diluted share, for the prior-year period.

Balance Sheet Highlights

The Company had cash and cash equivalents of $2.82 million as of March 31, 2015, compared with $4.61 million as of December 31, 2014. The decrease was primarily due to net cash used in operating activities of $.94 million as well as investing activities to fund the purchase of a license and deposits on and purchase of fixed assets of $.86 million. Our working capital decreased by $1.05 million during the three months from $12.37 million to $11.32 million.

Conference Call

To participate on the conference call on May 7, 2015 at 10:00 a.m. Eastern Time, please dial (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. In addition, following the completion of the call, a telephone replay will be accessible until May 14, 2015 at 11:59 p.m. Eastern Time by dialing (877) 660-6853 from the U.S. or (201) 612-7415 from outside the U.S. and entering conference ID #:13608374. Those interested in listening to the conference call live via the internet may do so by visiting the Investor Relations section of Chembio's website at www.chembio.com . The conference call may also be accessed via the internet at http://www.investorcalendar.com/IC/CEPage.asp?ID=173970 . An archive of the webcast will be available for 90 days on the Company's website at www.chembio.com .

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $8.0 billion point-of-care testing market. Chembio markets its DPP ® HIV 1/2 Assay and HIV 1/2 STAT-PAK® Assay in the U.S. and internationally. The Company's SURE CHECK ® HIV 1/2 Assay is marketed exclusively in the U.S. as Clearview ® Complete by a single entity. Outside the U.S., Chembio markets its SURE CHECK ® HIV 1/2 Assay primarily through distributors.

Chembio has developed a patented point-of-care (POC) test platform technology, the Dual Path Platform (DPP ® ) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products.

Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Chembio Diagnostic Systems, Inc. is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com .

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Results of Operations
     
  For the three months ended
  (UNAUDITED)
  March 31, 2015 March 31, 2014
 Net product sales   $ 5,614,685  $ 4,904,165
     
 License and royalty revenue   7,051  160
     
 R&D, milestone and grant revenue   609,401  908,748
     
 TOTAL REVENUES   $ 6,231,137  $ 5,813,073
     
 GROSS MARGIN   $ 2,686,618  $ 2,272,611
     
 Research and development expenses   $ 1,584,536  $ 1,197,622
     
 Selling, general and administrative expenses   $ 1,977,574  $ 1,457,728
     
 (LOSS) FROM OPERATIONS   $ (875,492)  $ (382,739)
     
 OTHER INCOME   $ 1,175  $ 1,830
     
 Income tax (benefit)   $ (227,500)  $ (156,170)
     
 NET (LOSS)   $ (646,817)  $ (224,739)
     
 Basic (loss) per share   $ (0.07)  $ (0.02)
     
 Diluted (loss) per share   $ (0.07)  $ (0.02)
     
 Weighted average number of shares outstanding, basic   9,624,691  9,339,181
     
 Weighted average number of shares outstanding, diluted   9,624,691  9,339,181
 
Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Balance Sheets
     
  March 31, 2015 December 31, 2014
  (UNAUDITED)  
CURRENT ASSETS:    
Cash and cash equivalents  $ 2,815,762  $ 4,614,538
Accounts receivable, net of allowance for doubtful accounts of $52,000 at March 31, 2015 and December 31, 2014, respectively  8,260,101  8,338,889
Inventories  3,698,623  3,638,299
Prepaid expenses and other current assets  1,427,579  1,066,473
TOTAL CURRENT ASSETS  16,202,065  17,658,199
     
FIXED ASSETS, net of accumulated depreciation   2,973,146  2,797,929
     
OTHER ASSETS  4,897,064  4,554,064
     
TOTAL ASSETS  $ 24,072,275  $ 25,010,192
     
CURRENT LIABILITIES:    
Accounts payable and accrued liabilities   $ 4,389,944  $ 4,946,030
Current portion of loans payable  --   -- 
Deferred revenue  495,677  340,000
TOTAL CURRENT LIABILITIES  4,885,621  5,286,030
     
TOTAL LIABILITIES  4,885,621  5,286,030
     
STOCKHOLDERS' EQUITY:    
Common stock -- $.01 par value; 100,000,000 shares authorized; 9,627,248 and 9,611,139 shares issued and outstanding for March 31, 2015 and December 31, 2014, respectively  96,273  96,112
Additional paid-in capital  47,665,574  47,556,426
Accumulated deficit  (28,575,193)  (27,928,376)
TOTAL STOCKHOLDERS' EQUITY  19,186,654  19,724,162
     
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $ 24,072,275  $ 25,010,192
 
Chembio Diagnostics, Inc. & Subsidiary
Summary of Consolidated Cash Flow
For the three months ended
(UNAUDITED)
  March 31, 2015 March 31, 2014
     
Net cash (used in) operating activities  $ (941,808)  $ (650,304)
Net cash (used in) investing activities  (856,968)  (66,789)
Net cash provided by financing activities  --   153,834
(DECREASE) IN CASH AND CASH EQUIVALENTS  $ (1,798,776)  $ (563,259)

Chembio Diagnostics Susan Norcott (631) 924-1135, ext. 125 Vida Strategic Partners (investor relations) Stephanie C. Diaz (415) 675-7401

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 95

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 72

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 39

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 86

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 39

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 138

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 125

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
OREF Opens $185,000 Research Grant Funding Cycle Today

Updated Category News Views 88

A hundred grand aimed at better graft science is not pocket change, but it is not a finished clinical program either. That distinction matters with the Orthopaedic Research and Education Foundation's newly opened $185,000 grant cycle. This is targeted, early-to-midstream research support: the sort of money that can produce usable data, sharpen a clinical question, and...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 125

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 144

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading

Top 5 Most Recently Viewed Articles

The Exclusion of XRP from Trump's Crypto Reserve Explained

Updated Category News Views 679

Understanding the Strategic Crypto Reserve Exclusion The cryptocurrency world was recently shaken when President Donald Trump issued an executive order that left notable omissions. Among these was XRP, a digital asset that Ripple and its supporters had hoped to see included in a U.S. sovereign crypto reserve. The Ripple Effects of Trump's Order After investing heavily in...

Continue Reading
UKG Stands Out as a Top Leader in Workforce Management Solutions

Updated Category News Views 168

UKG Secures Top Spot in Workforce Management UKG, a leading provider in HR, payroll, workforce management, and cultural solutions, has recently earned recognition for its exceptional contributions to the workforce management field. The company has been named a Leader in the NelsonHall New World Workforce Management 2024 evaluation, showcasing its strong performance across...

Continue Reading
Zillow Unveils Innovative AI Virtual Staging for Listings

Updated Category News Views 283

Zillow Introduces AI-Powered Virtual Staging In an exciting development for real estate, Zillow has recently launched an innovative feature known as Virtual Staging. This tool harnesses the power of artificial intelligence to enhance how listings are showcased, making the home-buying experience even more engaging for potential buyers. Creating a Visual Experience for Home...

Continue Reading
Balchem Corporation: Innovating Health and Nutrition Solutions

Updated Category News Views 296

Balchem Corporation's Upcoming Conference Presentation Balchem Corporation, a prominent global manufacturer known for its specialty ingredients aimed at health and nutrition markets, is set to make a significant presentation at an upcoming virtual conference. The CJS Securities New Ideas for the New Year Virtual Conference will feature notable company figures, including...

Continue Reading
Projected Growth of Cottonseed Oilseed Processing Market

Updated Category News Views 85

Overview of Cottonseed Oilseed Processing Market Growth The cottonseed oilseed processing market is experiencing significant growth, projected to reach $7.7 billion within a decade, showcasing a compound annual growth rate (CAGR) of 6.8%. The increasing demand for vegetable oils, primarily for their versatility and cost-effectiveness, plays a crucial role in this market's...

Continue Reading